[February 17, 2017] |
|
Drug-Eluting Stents Market 2015-2022 - Global Strategic Business Report 2017 with Abbott Laboratories, Boston Scientific & Medtronic Leading - Research and Markets
Research and Markets has announced the addition of the "Drug-Eluting
Stents - Global Strategic Business Report" report to their
offering.
The report provides separate comprehensive analytics for the US, Canada,
Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual
estimates and forecasts are provided for the period 2015 through 2022.
Also, a six-year historic analysis is provided for these markets. Market
data and analytics are derived from primary and secondary research. This
report analyzes the worldwide markets for Drug-Eluting Stents in US$
Million.
The report profiles 35 companies including many key and niche
players such as
-
Abbott Laboratories (US)
-
AlviMedica (Turkey)
-
Arterius Limited (UK)
-
B. Braun Melsungen AG (Germany)
-
Biosensors International Group, Ltd. (Singapore)
-
Shandong JW Medical Systems LTD. (China)
-
Biotronik SE & Co. KG (Germany)
-
Boston Scientific Corporation (US)
-
Cook Medical Inc. (US)
-
Elixir Medical Corp. (US)
-
KYOTO MEDICAL PLANNING Co., Ltd. (Japan)
-
Lepu Medical Technology (Beijing) Co., Ltd. (China)
-
Medtronic plc (Republic of Ireland)
-
Micell Technologies, Inc. (US)
-
Opto Circuits (India) Ltd (India)
-
Eurocor GmbH (Germany)
-
OrbusNeich Medical Company Limited (Hong Kong)
-
QualiMed (Germany)
-
Shanghai Microort Medical (Group) Co., Ltd. (China)
-
Sino Medical Sciences Technology Inc. (China)
-
STENTYS SA (France)
-
Terumo Corporation (Japan)
Key Topics Covered:
1. Industry Overview
2. Macro Growth Drivers
-
Aging - A Key Market Driver
-
Global Aging Population Demographic Statistics: Key Opportunity
Indicator
-
High Diabetes Incidence Worldwide Drives Demand for Cardiac Surgery
and Stents
3. Coronary Stenting - An Insight
-
Cardiovascular Diseases - A Brief Description
-
Coronary Heart Disease
-
Treatment Options for Coronary Artery Disease
-
Percutaneous Transluminal Coronary Angioplasty (PTCA)
-
Coronary Artery Bypass Graft (CABG)
-
Coronary Stenting
-
How is Coronary Stenting Performed - Procedure
-
Risks and Problems Associated with Placing a Stent
-
Restenosis - A Major Challenge
-
Cost and Price Economics of DES
-
Cost Evaluation of DES
-
Impact of DES on Indirect Costs
4. Product Launches & Approvals
-
MicroPort Medical Receives Marketing Approval in Argentina for
Firehawk® DES
-
MicroPort Medical's Firehawk® DES Receives Marketing Approval in Brazil
-
Biotronik Launches Biostem Clinical Trial for Orsiro Hybrid DES
-
Boston Scientific's Eluvia DES System Receives CE Mark
-
STENTYS Enters into Commercialization Agreements in Europe for
below-the-knee arterial DES
-
Medtronic Launches Expanded Sizes of Onyx DES and Expands Indications
-
Svelte Medical Launches SLENDER Coronary Stent System in Europe
-
Boston Scientific Receives FDA Approval for SYNERGY DES System
-
Medtronic Launches Resolute Onyx DES in India
5. Recent Industry Activity
-
Cordis Enters into Coronary Stent Sales Agreement with Biosensors
International
-
MicroPort Scientific Acquires DES Assets and Intellectual Property
from Cordis
6. Focus On Select Global Players
7. Global Market Perspective
Total Companies Profiled: 35 (including Divisions/Subsidiaries - 40)
- The United States (16)
- Japan (2)
- Europe (20)
- France (1)
- Germany (4)
- The United Kingdom (2)
- Rest of Europe (3)
- Asia-Pacific (Excluding Japan) (10)
- Middle East (1)
- Africa (1)
For more information about this report visit http://www.researchandmarkets.com/research/4rjckz/drugeluting
View source version on businesswire.com: http://www.businesswire.com/news/home/20170217005448/en/
[ Back To TMCnet.com's Homepage ]
|